Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Links shared publicly online about this topic.

1,313
total visits

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

View full resource at news-medical.net

Tags: Constipation, Cancer, Prostate Cancer, Prostate, Pharma, Clinical Trial, Men's Health, Oncology